Congestive heart failure in patients treated with doxorubicin

Cancer - Tập 97 Số 11 - Trang 2869-2879 - 2003
Sandra M. Swain1, Fredrick S. Whaley2, Michael S. Ewer3,4
1National Institutes of Health, Department of Health and Human Services, Bethesda, Maryland
2Global Statistics and Programming, Pharmacia, Kalamazoo, Michigan
3Department of Cardiology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas
4Department of Medical Affairs, The University of Texas M.D. Anderson Cancer Center, Houston, Texas

Tóm tắt

AbstractBACKGROUNDDoxorubicin is a highly effective and widely used cytotoxic agent with application that is limited by cardiotoxicity related to the cumulative dose of the drug. A large‐scale study that retrospectively evaluated the cardiotoxicity of doxorubicin reported that an estimated 7% of patients developed doxorubicin‐related congestive heart failure (CHF) after a cumulative dose of 550 mg/m2. To assess whether this estimate is reflective of the incidence in the broader clinical oncology setting, the authors evaluated data from three prospective studies to determine both the incidence of doxorubicin‐related CHF and the accumulated dose of doxorubicin at which CHF occurs.METHODSA group of 630 patients who were randomized to a doxorubicin‐plus‐placebo arm of three Phase III studies, two studies in patients with breast carcinoma and one study in patients with small cell lung carcinoma, were included in the analysis.RESULTSThirty‐two of 630 patients had a diagnosis of CHF. Analysis indicated that an estimated cumulative 26% of patients would experience doxorubicin‐related CHF at a cumulative dose of 550 mg/m2. Age appeared to be an important risk factor for doxorubicin‐related CHF after a cumulative dose of 400 mg/m2, with older patients (age > 65 years) showing a greater incidence of CHF compared with younger patients (age ≤ 65 years). In addition, > 50% of the patients who experienced doxorubicin‐related CHF had a reduction < 30% in left ventricular ejection fraction (LVEF) while they were on study.CONCLUSIONSDoxorubicin‐related CHF occurs with greater frequency and at a lower cumulative dose than previously reported. These findings further indicate that LVEF is not an accurate predictor of CHF in patients who receive doxorubicin. Cancer 2003;97:2869–79. © 2003 American Cancer Society.DOI 10.1002/cncr.11407

Từ khóa


Tài liệu tham khảo

10.7326/0003-4819-91-5-710

10.1200/JCO.1997.15.4.1318

10.1200/JCO.1997.15.4.1333

Feldmann J, 1992, Advanced small cell lung cancer treated with CAV (cyclophosphamide‐Adriamycin® + vincristine) chemotherapy and the cardioprotective agent dexrazoxane (ADR‐529, ICRF‐187, Zinecard®), Proc Am Soc Clin Oncol., 11, 296

The Criteria Committee of the New York Heart Association, 1994, Nomenclature and criteria for diagnosis of diseases of the heart and great vessels, 253

10.1200/JCO.1992.10.1.117

10.1016/0002-9343(87)90212-9

10.1177/000331979905000105

10.1200/JCO.1999.17.7.2237

10.1161/01.CIR.96.8.2641

Mason J, 1978, Invasive and noninvasive methods of assessing Adriamycin cardiotoxic effects in man: superiority of histopathologic assessment using endomyocardial biopsy, Cancer Treat Report., 62, 857

10.7326/0003-4819-96-2-133

10.1200/JCO.1985.3.6.818

10.1200/JCO.1998.16.11.3502

10.1093/annonc/mdf132

Kanter P, 1993, Comparison of the cardiotoxic effects of liposomal doxorubicin (TLC D‐99) versus free doxorubicin in beagle dogs, In Vivo., 7, 17

Working P, 1999, Reduction of the cardiotoxicity of doxorubicin in rabbits and dogs by encapsulation in long‐circulating, pegylated liposomes, J Pharmacol Exp Ther., 289, 1128

10.1200/JCO.1999.17.5.1425

10.1023/A:1008216430806

10.1126/science.877547

Herman E, 1981, Reduction of chronic doxorubicin cardiotoxicity in dogs by pretreatment with (+/−)‐1,2‐bis(3,5 dioxopiperazinyl‐1‐yl)propane (ICRF‐187), Cancer Res., 41, 3436

10.1111/j.1749-6632.1982.tb31279.x

Myers C, 1983, A randomized controlled trial assessing the prevention of doxorubicin cardiomyopathy by N‐acetylcysteine, Semin Oncol., 10, 53

Iliskovic N, 1997, Lipid lowering: an important factor in preventing Adriamycin‐induced heart failure, Am J Pathol., 150, 727

Thông tin
Thông tin xuất bản

Cancer

Tập 97 Số 11

2869-2879

Thông tin tác giả